Mesoblast begins Phase 3 trial of Rexlemestrocel-L for chronic low back pain due to inflammatory degenerative disc disease, targeting a 12-month primary endpoint of pain reduction.

Mesoblast Limited starts patient enrollment for a pivotal Phase 3 trial of Rexlemestrocel-L for chronic low back pain due to inflammatory degenerative disc disease. The U.S. FDA has confirmed trial design, a 12-month primary endpoint of pain reduction, and designated Rexlemestrocel-L as a Regenerative Medicine Advanced Therapy. This therapy could reduce or eliminate opioid use, addressing a significant need for patients with chronic low back pain.

July 22, 2024
3 Articles